Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab repeated dose-finding study in children and adolescents with systemic juvenile idiopathic arthritis
2015-004000-35Phase 2Unknown
- Sponsor
- Sanofi
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of sarilumab in systemic juvenile idiopathic arthritis (SJIA) (2 arms), sponsored by Sanofi. Primary endpoint: Maximum serum concentration observed. Status: unknown.
02
Drugs
sarilumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on 2015-004000-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004000-35.